Coherus Oncology, Inc. CHRS

Rank #1823 · Nasdaq · $0.1B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

41.4

P/E

4.5

P/B

-0.66

ROE

-14.7%

Op. Margin

-756.6%

Debt Ratio

-300%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E 4.5x, P/B -0.66x. Ranks in the top 52% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -14.7%. Ranks in the top 88% of the universe.

Safety ★★★★★

Excellent

Debt ratio -300%. Ranks in the top 4% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆

Poor

Revenue decline of 87.5% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2014	–	$-0.0B	$-0.0B	$-0.1B	–	-93
2015	–	$-0.0B	$-0.1B	$0.1B	–	180
2016	–	$-0.1B	$-0.1B	$-0.0B	–	-3533
2017	–	$-0.2B	$-0.2B	$0.0B	–	775
2018	$0.2B	$-0.1B	$-0.1B	$0.0B	-61.0	415
2019	$0.0B	$-0.2B	$-0.2B	$0.0B	-14918.8	713
2020	$0.0B	$-0.2B	$-0.2B	$0.0B	–	995
2021	$0.4B	$0.1B	$0.1B	$-0.0B	30.3	-1453
2022	$0.5B	$0.2B	$0.1B	$0.1B	32.9	553
2023	$0.3B	$-0.3B	$-0.3B	$0.3B	-80.8	220
2024	$0.2B	$-0.3B	$-0.3B	$0.1B	-121.7	842
2025	$0.0B	$-0.2B	$0.0B	$-0.2B	-756.6	-300